Scarica l'app Stockscreener
74.87
1.53%
1.13
Dopo l'orario di chiusura:
74.87
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$73.74
Aprire:
$73.49
Volume 24 ore:
6.12M
Relative Volume:
1.18
Capitalizzazione di mercato:
$28.89B
Reddito:
$4.82B
Utile/perdita netta:
$930.40M
Rapporto P/E:
32.02
EPS:
2.3381
Flusso di cassa netto:
$1.43B
1 W Prestazione:
+3.84%
1M Prestazione:
+22.04%
6M Prestazione:
+17.87%
1 anno Prestazione:
-12.74%
Intervallo 1D:
$72.50
$76.34
Intervallo di 1 settimana:
$69.60
$76.34
Portata 52W:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
74.87 | 28.45B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
87.78 | 149.10B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
299.46 | 116.96B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
73.98 | 94.76B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
47.98 | 71.81B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
88.16 | 49.79B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Iniziato | Evercore ISI | In-line |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
Dexcom Inc. stock (US2521311074): shares trade mixed as investors look beyond latest earnings and gu - AD HOC NEWS
Dexcom Inc. stock (US2521311074): institutional buying and technical picture on Nasdaq - AD HOC NEWS
Stolen medical devices that failed quality control were sold to the public - Yahoo
Elliott to get two board seats at Dexcom ahead of investor day - MSN
DexCom Inc. stock underperforms Friday when compared to competitors - MSN
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Dexcom Inc. stock (US2521311074): shares edge lower after recent Nasdaq volatility - AD HOC NEWS
Dexcom, Inc. 8-K Filing Summary: Company Details, Stock Info, and Regulatory Compliance (May 27, 2026) - Minichart
DXCM News | DEXCOM INC (NASDAQ:DXCM) - ChartMill
DXCM Stock Price, Quote & Chart | DEXCOM INC (NASDAQ:DXCM) - ChartMill
DexCom, Inc. (DXCM) Announces Results of 2026 Annual Meeting of Stockholders - GuruFocus
Dexcom Shareholders Approve Board, Auditor and Compensation - TipRanks
Dexcom (NASDAQ: DXCM) investors approve board slate, auditor and executive pay - Stock Titan
Dexcom Discovers Theft of Scrapped G7 CGM Sensors - Medical Product Outsourcing
Citigroup Adjusts Price Target on DexCom to $84 From $79, Maintains Buy Rating - marketscreener.com
Signos raises $20M, expands Dexcom partnership for weight loss - qz.com
Dexcom says some CGM sensors intended for scrap stolen and resold - MSN
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Dexcom (NASDAQ: DXCM) CEO has shares withheld to cover RSU taxes - Stock Titan
Dexcom (DXCM) EVP has 1,451 shares withheld for RSU tax obligations - Stock Titan
Dexcom (NASDAQ: DXCM) CFO has 1,451 RSU shares withheld for taxes - Stock Titan
Dexcom (NASDAQ: DXCM) EVP shares withheld to cover RSU tax obligations - Stock Titan
Dexcom (DXCM) EVP Coleman has 7,362 shares withheld to cover RSU taxes - Stock Titan
Elliott strikes Dexcom board settlement after taking stake - MSN
Signos, Inc announced that it has received $20 million in funding from GV Management Company, LLC, DexCom, Inc., Blue Cross and Blue Shield of Alabama - marketscreener.com
How The DexCom (DXCM) Investment Story Is Shifting With New Guidance And Valuation Resets - Yahoo Finance
Signos grows foothold in weight loss wave fueled by GLP-1s with its AI health data tracking - CNBC
Signos, Inc., Maker of the First FDA-cleared CGM System for Weight Management, Raises $20 Million to Accelerate Growth - Business Wire
TD Cowen Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $75 - Moomoo
Goldman Sachs Adjusts Price Target on DexCom to $85 From $80, Maintains Buy Rating - marketscreener.com
DexCom Faces Product Safety Incident, Stock Drops 4% - GuruFocus
Dexcom (DXCM) chair’s 10b5-1 sale leaves 382,482 shares held - Stock Titan
Dexcom recalls stolen G7 sensors sold by unauthorized vendor By Investing.com - Investing.com India
DexCom (DXCM) Alerts Customers About Stolen G7 Sensors - GuruFocus
Dexcom warns of scrapped glucose sensors being resold - MedTech Dive
Dexcom warns patients as stolen glucose sensors hit the market - Reuters
Dexcom recalls stolen G7 sensors sold by unauthorized vendor - Investing.com UK
DexCom Reports Theft of Scrapped G7 Glucose Monitor Sensors - marketscreener.com
Dexcom uncovers theft of scrapped product, notifies potentially impacted users - marketscreener.com
Dexcom Inc. stock (US2521311074): diabetes-tech player draws fresh fund flows and cautious optimism - AD HOC NEWS
Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users - The Joplin Globe
DXCM to launch Dexcom Flex CGM system for type 2 diabetes in Germany - MSN
Dexcom’s SWOT analysis: stock faces competitive headwinds in 2026 By Investing.com - Investing.com India
Dexcom’s SWOT analysis: stock faces competitive headwinds in 2026 - Investing.com UK
DexCom, Inc. (DXCM) Stock Analysis: Strong Buy Ratings Signal Potential Upside - DirectorsTalk Interviews
Dexcom stock (US2521311074): earnings beat and fresh institutional interest keep CGM story in focus - AD HOC NEWS
How Dexcom Inc. (DXCM) Affects Rotational Strategy Timing - Stock Traders Daily
DexCom, Inc.Common Stock (Nasdaq:DXCM) Stock Quote - FinancialContent
Does DexCom’s (DXCM) Flex Launch in Germany Hint at a Broader CGM Access Strategy Shift? - simplywall.st
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.56%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):